Parkinson's Diseases

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

By

The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.

Mild TBI May Increase Risk of Parkinson Disease

Mild TBI May Increase Risk of Parkinson Disease

Mild traumatic brain injury is associated with increased risk of Parkinson disease among military veterans.

Long-Term Benefits of Gocovri Observed in PD Patients With Dyskinesia

Long-Term Benefits of Gocovri Observed in PD Patients With Dyskinesia

By

By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.

Amantadine Now Available to Treat Parkinson Disease Dyskinesia

Amantadine Now Available to Treat Parkinson Disease Dyskinesia

By

Adamas announced that Gocovri extended-release capsules are now available for the treatment of dyskinesia in Parkinson's patients.

Focused Ultrasound Thalamotomy Promising for Reducing Refractory Tremor in Parkinson Disease

Focused Ultrasound Thalamotomy Promising for Reducing Refractory Tremor in Parkinson Disease

By

The efficacy of focused ultrasound thalamotomy was evaluated for management of medically refractory, tremor-dominant Parkinson disease.

Sign Up for Free e-newsletters



CME Focus